Company Description
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific.
Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis.
In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives.
Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients.
The company was incorporated in 2011 and is headquartered in Fremont, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jun 20, 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Christopher Hall |
Contact Details
Address: 6600 Dumbarton Circle Fremont, California 94555 United States | |
| Phone | 650 752 1300 |
| Website | personalis.com |
Stock Details
| Ticker Symbol | PSNL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001527753 |
| CUSIP Number | 71535D106 |
| ISIN Number | US71535D1063 |
| Employer ID | 27-5411038 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Christopher M. Hall | President, Chief Executive Officer and Director |
| Aaron L. Tachibana | Chief Financial Officer and Chief Operating Officer |
| Stephen M. Moore J.D. | Senior Vice President and Chief Legal Officer |
| Dr. Richard Chen M.D., M.S. | Executive Vice President of Research & Development and Chief Medical Officer |
| Dr. Russ B. Altman M.D., Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Michael P. Snyder Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Michael J Fitzpatrick | Vice President of Worldwide Sales |
| Dr. Christian Haudenschild Ph.D. | Senior Vice President of Genomic Laboratory Operations |
| Stephane Mouradian Ph.D. | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 19, 2024 | 8-K | Current Report |
| Sep 11, 2024 | EFFECT | Notice of Effectiveness |
| Sep 9, 2024 | UPLOAD | Filing |
| Aug 30, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |